Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 6 to 7 amino acid residues in defined sequence
Reexamination Certificate
2006-08-29
2006-08-29
Russel, Jeffrey Edwin (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
6 to 7 amino acid residues in defined sequence
C530S333000
Reexamination Certificate
active
07098307
ABSTRACT:
The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.
REFERENCES:
patent: 4299838 (1981-11-01), Durlach
patent: 4331646 (1982-05-01), Delaage
patent: 4518587 (1985-05-01), Laruelle et al.
patent: 5393740 (1995-02-01), Amagaya et al.
patent: 5631265 (1997-05-01), Audia et al.
patent: 6046180 (2000-04-01), Jackson et al.
patent: 6214790 (2001-04-01), Richelson et al.
patent: 6765099 (2004-07-01), Richelson et al.
patent: 6921805 (2005-07-01), Richelson et al.
patent: 0 333 071 (1989-09-01), None
patent: WO 96/03400 (1996-02-01), None
patent: WO 96/39162 (1996-12-01), None
patent: WO 97/48400 (1997-12-01), None
Al-Rodhan et al., “Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem,”Brain Res., 1991, 557:227-235.
Bissette et al., “Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin,”Nature, 1976, 262:607-609.
Carraway and Leeman, “The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami,”J. Biol. Chem., 1973, 248:6854-6861.
Clineschmidt and McGuffin, “Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli,”Eur. J. Pharmacol., 1977, 46:395-396.
Cusack et al., “Pharmacological studies on novel neurotensin mimetics: discovery of a pharmacologically unique agent exhibiting concentration-dependent dual effects as antagonist and agonist,”Mol. Pharmacol., 1993, 44:1036-1040.
Cusack et al., “Pharmacological and biochemical profiles of unique neurotensin 8-13 analogs exhibiting species selectivity, stereoselectivity, and superagonism,”J. Biol. Chem., 1995, 270:18359-18366.
Fauq et al., “Synthesis of (2S)-2-amino-3-(1H-4-indolyl) propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides,”Tetrahedron: Asymmetry, 1998, 9:4127-4134.
Huang and Hanson, “Differential effect of haloperidol on release of neurotensin in extrapyramidal and limbic systems,”Eur. J. Pharmacol., 1997, 332:15-21.
Jolicoeur et al., “Differential neurobehavioral effects of neurotensin and structural analogues,”Peptides, 1981, 2:171-175.
Kitabgi et al. “Neurotensin binding to extraneural and neural receptors: comparison with biological activity and structure-activity relationships,”Mol. Pharmacol., 1980, 18:11-19.
Lambert et al., “Anatomy and mechanisms of neurotensin-dopamine interactions in the central nervous system,”Ann. N.Y. Acad. Sci., 1995, 757:377-389.
Li et al., “Neurotensin peptides antagonistically regulate postsynaptic dopamine D2receptors in rat nucleus accumbens: a receptor binding and microdialysis study,”J. Neural. Transm., 1995, 102:125-137.
Morbeck et al., “Analysis of hormone-receptor interaction sites using synthetic peptides: Receptor binding regions of the alpha-subunit of human choriogonadotropin,”Methods: A Companion to Methods in Enzymology, 1993, 5:191-200, Academic Press Inc., New York.
Radke et al., “Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions,”Proc. Natl. Acad. Sci. USA, 1998, 95:11462-11464.
Sarhan et al., “Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist,”Peptides, 1997, 18(8):1223-1227.
Snijders et al., “Neurotensin induces catalepsy in mice,”Neuropharmacology, 1982, 21:465-468.
Troxler von Franz, “Praparative verwendung von mannich-basen von hydroxy-indolen als alkylierungsmittel,”Helvetica Chimica Acta, 1968, Volumen 51, Fasciculus 6, pp. 1214-1224.
Tyler et al., “In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier,”Neuropharmacology, 1999, 38:1027-1034.
Vincent Jean-Pierre et al., “Neurotensin and neurotensin receptors,”TIPS, 1999, 20:302-309.
Boules Mona
Cusack Bernadette Marie
Fauq Abdul
McCormick Daniel J.
Pang Yuan-Ping
Fish & Richardson P.C.
Mayo Foundation for Medical Education and Research
Russel Jeffrey Edwin
LandOfFree
Neo-tryptophan does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neo-tryptophan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neo-tryptophan will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3659333